CGTX Stock Summary and Trading Ideas (Cognition Therapeutics | NASDAQ:CGTX)

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics trades on the NASDAQ stock market under the symbol CGTX.

As of December 26, 2025, CGTX stock price declined to $1.45 with 389,070 million shares trading.

CGTX has a beta of 1.87, meaning it tends to be more sensitive to market movements. CGTX has a correlation of 0.04 to the broad based SPY ETF.

CGTX has a market cap of $127.92 million. This is considered a Micro Cap stock.

In the last 3 years, CGTX traded as high as $3.83 and as low as $.22.

The top ETF exchange traded funds that CGTX belongs to (by Net Assets): VTI, VXF, IBRN.

CGTX has outperformed the market in the last year with a return of +123.8%, while the SPY ETF gained +16.0%. In the last 3 month period, CGTX beat the market returning +7.4%, while SPY returned +4.7%. However, in the most recent 2 weeks CGTX has underperformed the stock market by returning -14.2%, while SPY returned +0.7%.

CGTX support price is $1.38 and resistance is $1.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGTX shares will trade within this expected range on the day.